Related Experiment Video

Updated: Aug 12, 2025

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

168

Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian

Hai-Bin Chen1, Yao-Lin Yang1, Rong-Sen Meng1

  • 1Department of Cardiology, Guangdong Second Provincial General Hospital, Guangzhou, Guangdong, China, 510317.

ESC Heart Failure
|January 26, 2023
PubMed
Abstract

Insights

This study found no significant differences in major outcomes among SGLT2 inhibitors for heart failure patients. However, sotagliflozin showed a trend towards lower composite events, while dapagliflozin suggested reduced mortality risks.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Direct head-to-head comparisons of SGLT2 inhibitors in heart failure are lacking.
  • This study provides an indirect comparison of SGLT2 inhibitor treatments in established heart failure.

Approach:

  • A systematic review and Bayesian network meta-analysis of randomized controlled trials comparing SGLT2 inhibitors versus placebo in heart failure patients.
  • Included five trials encompassing four treatment strategies.

Key Points:

  • No significant differences were observed for the composite of cardiovascular death or hospitalization for heart failure (HF) among dapagliflozin, empagliflozin, and sotagliflozin.
  • All-cause mortality, cardiovascular death, and hospitalization for HF also showed no significant differences between these SGLT2 inhibitors.
  • Sotagliflozin showed a trend towards the lowest risk for the composite outcome, while dapagliflozin suggested the lowest risk for all-cause and cardiovascular mortality.

Conclusions:

  • Among patients with established heart failure, SGLT2 inhibitor treatments demonstrated comparable efficacy for major clinical outcomes.
  • Individual SGLT2 inhibitors may offer differential benefits, with sotagliflozin potentially reducing composite events and dapagliflozin potentially reducing mortality.
Keywords:
Cardiovascular deathHeart failureHospitalization for heart failureIndirect comparisonSGLT2 inhibitors

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

713
In Silico Clinical Trials for Cardiovascular Disease09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

1.8K

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
664
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
24
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
412
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
441